Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity - Investors | Eli Lilly and Company
- Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and Company
- Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study CNBC
- Live news: Eli Lilly’s weight loss drug cuts the risk of heart failure in latest trial Financial Times
- Video Study suggests Zepbound can help patients dealing with heart failure ABC News